Form 12b-25.--NOTIFICATION OF LATE FILING
FORM 12b-25
SEC FILE NUMBER
0-26126
CUSIP NUMBER
817523 10 3
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
/Check One/. X Form 10-K Form 20-F Form 11-K Form 10 Q Form N-SAR
For Period Ended: December 26, 1999
-----------------
/ / Transition Report on Form 10-K
/ / Transition Report on Form 20-F
/ / Transition Report on Form 11-K
/ / Transition Report on Form 10-Q
/ / Transition Report on Form N-SAR
For the Transition Period Ended:
-------------------------
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates:
PART I--REGISTRANT INFORMATION
Serologicals Corporation
- -----------------------------------------------------------------------------
Full Name of Registrant
Serologicals Holdings, Inc.
- -----------------------------------------------------------------------------
Former Name if Applicable
780 Park North Blvd., Suite 110
- -----------------------------------------------------------------------------
Address Principal Executive Office (Street and Number)
Atlanta, Georgia 30021
- -----------------------------------------------------------------------------
City State and Zip Code
PART II--Rules 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate)
/X/ (a) The reasons described in reasonable detail in Part III of
this form could not be eliminated without unreasonable effort or
expense;
/X/ (b) The subject annual report, semi-annual report, transition
report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or portion
thereof, will be filed on or before the fifteenth calendar day
following the prescribed due date; or the subject quarterly
report of transition report on Form 10-Q, or portion thereof will
be filed on or before the fifth calendar day following the
prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III--NARRATIVE
State below in reasonable detail the reasons why the Form 10-K, 11-K, 10-Q,
N-SAR, or the transition report or portion thereof, could not be filed within
the prescribed time period. (Attach Extra Sheets if Needed)
The annual report on Form 10-K for Serologicals Corporation (the "Company")
could not be filed within the prescribed time period, as the Company's
audited financial statements have not been completed and could not be
completed without unreasonable effort or expense. The Company anticipates
that its report on Form 10-K will be filed on or before the fifteenth
calendar day following its prescribed due date.
PART IV-OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Peter J. Pizzo, III 404 296-5595
------------------- ------- ---------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s). X Yes No
---
- -----------------------------------------------------------------------------
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by
the earnings statement to be included in the subject report or portion
thereof?
X Yes No
---
If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
The Company anticipates reporting results of operations for 1999
significantly lower than the prior period, primarily as a result of: (i)
special charges of approximately $8.6 million recorded in the third quarter
of 1999 and reported in the Company's quarterly report on Form 10-Q for such
period; and (ii) a non-cash asset impairment charge of approximately $23-$26
million relating to the Company's non-specialty antibody business that is
anticipated to be recorded in the fourth quarter of 1999.
- -----------------------------------------------------------------------------
SEROLOGICALS CORPORATION
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date March 27, 2000
-----------------------------------
By /s/Peter J. Pizzo, III
-----------------------------------
Chief Financial Officer
INSTRUCTION: The form may be signed by an executive officer of the registrant
or by any other duly authorized representative. The name and title of the
person signing the form shall be typed or printed beneath the signature. If
the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the
representative's authority to sign on behalf of the registrant shall be filed
with the form.
ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001).
